SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-049091
Filing Date
2023-10-23
Accepted
2023-10-23 06:00:19
Documents
13
Period of Report
2023-10-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20012978_8k.htm   iXBRL 8-K 36022
2 EXHIBIT 99.1 ef20012978_ex99-1.htm EX-99.1 26623
  Complete submission text file 0001140361-23-049091.txt   215927

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20231022.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20231022_lab.xml EX-101.LAB 23290
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20231022_pre.xml EX-101.PRE 16550
7 EXTRACTED XBRL INSTANCE DOCUMENT ef20012978_8k_htm.xml XML 4375
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

IRS No.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 231338415
SIC: 2834 Pharmaceutical Preparations